05/07/2015 19:21:51 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
06/29/20159:27AMDJNMerck Regimen to Reduce Nausea Meets Primary Endpoint
By Chelsey Dulaney Merck & Co. said Monday that its experimental drug regimen to reduce nausea in patients receiving chemotherapy met its primary endpoint goal in a late-stage study. The phase-three study combined Merck's injectable fosaprepitant dimeglumine, called Emend, with antivomiting medicines. Merck said the... More...>>
06/29/20158:30AMBWMerck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint i...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant dimeglumine) for Injection, Merck’s substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines... More...>>
06/29/20158:00AMPRNUSSanofi Pasteur and Merck Vaccines Appoint David Khougazian as President of Sanofi Pasteur MSD
Sanofi Pasteur and Merck Vaccines Appoint David Khougazian as President of Sanofi Pasteur MSD PR Newswire LYON, France, June 29, 2015 LYON, France, June 29, 2015 /PRNewswire/ -- MSD, known as Merck in the United States and Canada (NYSE: MRK) and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY... More...>>
06/26/20158:00AMBWMerck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
06/21/201511:06AMTMFWhat Is Cancer Immunotherapy?
http://www.fool.com/investing/general/2015/06/21/what-is-immunotherapy.aspx?source=eptadnlnk0000002 More...>>
06/19/20157:58AMTMFWhy Bristol-Myers Squibb Co.'s Stock Could Sink
http://www.fool.com/investing/general/2015/06/19/why-bristol-myers-squibb-cos-stock-could-sink.aspx?source=eptadnlnk0000002 More...>>
06/17/20155:43PMDJNInspire Pharmaceuticals Settles Federal Fraud Claims
By Maria Armental Inspire Pharmaceuticals Inc. has agreed to pay $5.9 million and admit to making misleading marketing claims of its drug AzaSite to settle federal fraud claims, the Justice Department said Wednesday. Under the settlement, which was approved Monday in Manhattan U.S. District Court, company officials admitted... More...>>
06/15/20152:50PMDJNEU Approves Merck KGaA $17 Billion Purchase of Sigma-Aldrich
BRUSSELS—The European Union's antitrust authorities on Monday approved German pharmaceutical company Merck KGaA's $17 billion proposed purchase of Sigma-Aldrich Corp , a U.S. supplier of laboratory testing materials, but said they were setting a number of conditions on the deal. The Merck Millipore division focuses... More...>>
06/15/201510:14AMTMFIs Medicare in Danger from Free Trade?
http://www.fool.com/retirement/general/2015/06/15/is-medicare-in-danger-from-free-trade.aspx?source=eptadnlnk0000002 More...>>
06/13/20151:16PMTMFWhy I'm Shorting Biotech
http://www.fool.com/investing/general/2015/06/13/why-im-shorting-biotech.aspx?source=eptadnlnk0000002 More...>>
06/11/20159:00AMPRNUSLiaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus
Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus Merck and Liaison collaboration on North Carolina State University campus to foster innovation in the life sciences and healthcare industries PR Newswire ATLANTA, June 11, 2015 ATLANTA, June 11, 2015 /PRNewswire/... More...>>
06/11/20158:00AMPRNUSMerck Launches New Program That Encourages Women to "Rule the Real Talk" and Prioritize Their Sexual Health
Merck Launches New Program That Encourages Women to "Rule the Real Talk" and Prioritize Their Sexual Health Survey Reveals Women Avoid Crucial Conversations with Partners and Health Care Providers, Including Discussions about Birth Control Options PR Newswire KENILWORTH, N.J., June 11, 2015 KENILWORTH, N.J... More...>>
06/10/201510:05AMTMFCancer Stocks: 2 to Sell, 1 to Buy
http://www.fool.com/investing/general/2015/06/10/cancer-stocks-2-to-sell-1-to-buy.aspx?source=eptadnlnk0000002 More...>>
06/10/201510:05AMTMFCancer Stocks: 2 to Sell, 1 to Buy
http://www.fool.com/investing/general/2015/06/10/cancer-stocks-2-to-sell-1-to-buy.aspx?source=eptadnlnk0000002 More...>>
06/10/20158:46AMBWMerck & Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), & SB2, Rem...
Data Presented for the First Time at the EULAR Annual Meeting Phase 1 Data for SB2, SB4 and SB5, an Investigational Biosimilar of Humira (Adalimumab), also Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced that pivotal Phase 3 clinical studies of... More...>>
06/10/20158:30AMPRNCAMerck et Samsung Bioepis annoncent que des études pivots de phase III portant sur le SB4, Enbrel (étanercept) et le SB2, Re...
Merck et Samsung Bioepis annoncent que des études pivots de phase III portant sur le SB4, Enbrel (étanercept) et le SB2, Remicade (infliximab), deux produits biosimilaires expérimentaux, ont permis de confirmer les paramètres principaux Canada NewsWire KIRKLAND, QC, KENILWORTH, NJ et SÉOUL, CORÉE... More...>>
06/10/20158:30AMPRNCAMerck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2,...
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints Canada NewsWire KIRKLAND, QC, KENILWORTH, N.J., and SEOUL, South Korea, June 10, 2015 Data Presented for the First Time at the EULAR Annual Meeting Phase... More...>>
06/10/20157:00AMPRNCAL'étude TECOS de Merck, qui évalue le profil d'innocuité cardiovasculaire de JANUVIA (sitagliptine), a permis de confirmer...
L'étude TECOS de Merck, qui évalue le profil d'innocuité cardiovasculaire de JANUVIA (sitagliptine), a permis de confirmer le paramètre principal chez des patients atteints de diabète de type 2 Canada NewsWire KIRKLAND, QC, le 10 juin 2015 Les résultats ont été publiés dans la revue New England Journal of Medicine... More...>>
06/10/20157:00AMPRNCATECOS, Merck's Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
TECOS, Merck's Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes Canada NewsWire KIRKLAND, QC, June 10, 2015 Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin... More...>>
06/10/20156:40AMBWTECOS, lo studio clinico di MSD sulla sicurezza cardiovascolare di JANUVIA (sitagliptin), ha incontrato l'endpoint primario n...
I risultati pubblicati nel New England Journal of Medicine e presentati durante le sessioni scientifiche della American Diabetes Association Il trattamento con sitagliptin non ha aumentato il rischio di importanti eventi avversi cardiovascolari nell'endpoint primario composito o il ricovero per scompenso cardiaco, rispetto... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150705 19:21